FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies
pharmaphorum
OCTOBER 19, 2020
Combination therapies involving Roche and AbbVie’s cancer drug Venclexta have been formally approved by the FDA in acute myeloid leukaemia, following supportive data from late-stage studies. The combination therapies had previously been marketed following accelerated approval in November 2018 on the basis of early stage results.
Let's personalize your content